Malcisbo
Schlieren, Zurich, Switzerland
About Malcisbo
Malcisbo develops novel carbohydrate-based vaccines for human and animal health. Their focus is on parasitic diseases, on human food safety and on zoonotic diseases. The company has developed its proprietary target discovery platform to identify carbohydrates as vaccine targets. Combined with their glycoengineering technologies, novel and efficient glycoconjugate vaccines are being developed. Malcisbo is developing a strong pipeline of novel vaccine products coming out this platform for unmet needs in human and veterinary medicine targeting large markets. It is Malcisbo’s goal to develop affordable vaccines to protect people in underdeveloped areas against parasitic worm infections (e.g., helminthic infections by hookworm, filaria or schistosoma).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $124.2K
- Funding stage: Seed
- Last round: Pre-Seed (Jul 2010)
- Website: malcisbo.com
- Phone: 41 44 633 78 87
Industries & Categories
Biotechnology, Health Care, Medical, Test and Measurement
Social Profiles
Canonical: https://fsome.com/organization/malcisbo-2515534 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.